2025 WMIF | Hematological Cancers | Emerging Treatments

Описание: Over the past few decades, application of immunotherapy in cancer has gone from concept to successful therapy. In particular, manipulation and modification of T-cells has led to exciting results in treating heme malignancies such as acute and chronic leukemia, lymphomas, and multiple myeloma. In particular, CAR-T therapies and bispecific antibodies have shown success in treating several such cancers and have moved from drugs of last resort to earlier lines of therapy. This panel will discuss the progress that has resulted from introduction of highly targeted bispecific antibodies, as well as cell and gene hybrid therapies such as CAR-T and will address challenges for future developments.

Moderators
Tim Anderson, MD, Pharmaceutical Analyst, BofA Securities
Alec Stranahan, SMid-Cap Biotech Analyst, BofA Securities

Speakers
Amir Fathi, MD, Director, Leukemia Program, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School
Connor Johnson, MD, Assistant Professor of Medicine, Massachusetts General Hospital & Harvard Medical School
Rosanna Ricafort, MD VP, Head of Global Program Leadership, Hematology and Cell Therapy Drug Development, Bristol Myers Squibb
Andrew Yee, MD, Clinical Director, Center for Multiple Myeloma, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School